In: Oncology Research and Treatment, 46 (2023), Nr. 7-8. pp. 320-325. ISSN 2296-5270 (Druck-Ausg.); 2296-5262 (Online-Ausg.)
Preview |
PDF, English
- main document
Download (327kB) | Terms of use |
Abstract
Introduction: Esophagogastric adenocarcinoma (EGA) is one of the leading causes of cancer-related mortality worldwide. Therapeutic options are limited for patients with recurrent or metastatic disease. Targeted therapy may be a suitable treatment for selected patients, but its efficacy remains elusive. Case Presentation: Here, a 52-year-old male patient with advanced EGA Siewert Type II shows a significant response to combination therapy with olaparib and pembrolizumab. After progression following first- and second-line therapy, including a programmed cell death ligand 1 (PD-L1) inhibitor, next-generation sequencing of a tumor sample was performed to identify possible molecular targets. A mutation in RAD51C, a member of the homology-directed repair (HDR) system, was identified in addition to high PD-L1 expression. As a result, therapy with the poly-(ARD-Ribose) polymerase (PARP) inhibitor olaparib and the programmed cell death protein 1 (PD1)-inhibitor pembrolizumab was initiated. A durable partial response lasting for more than 17 months was observed. A second molecular profiling from a newly occurring subcutaneous metastasis showed a loss of FGF10 but no fluctuations in the gene alteration of RAD51C and SMARCA4. Interestingly, the new lesion showed HER2-positivity (immunohistochemistry 3+ and fluorescence in situ hybridization [FISH]-positivity) in 30% of tumor cells. Conclusion: In this case, a long-lasting response to the combination of olaparib and pembrolizumab was observed despite previous treatment with a PD-L1 inhibitor. This case illustrates the need for further clinical trials to analyze the efficacy of PARP inhibitor combinations in EGA.
Document type: | Article |
---|---|
Journal or Publication Title: | Oncology Research and Treatment |
Volume: | 46 |
Number: | 7-8 |
Publisher: | S. Karger AG, Medical and Scientific Publishers |
Place of Publication: | Basel, Switzerland |
Edition: | Zweitveröffentlichung |
Date Deposited: | 19 Aug 2024 09:24 |
Date: | 2023 |
ISSN: | 2296-5270 (Druck-Ausg.); 2296-5262 (Online-Ausg.) |
Number of Pages: | 6 |
Page Range: | pp. 320-325 |
Faculties / Institutes: | Medizinische Fakultät Heidelberg > Medizinische Universitäts-Klinik und Poliklinik |
DDC-classification: | 610 Medical sciences Medicine |
Additional Information: | Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich. *** This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively. |